|
Published by: Global Markets Direct
Published: Jun. 28, 2012 - 26 Pages
Table of Contents- Introduction
Global Markets Direct Report Coverage - Kaposi's Sarcoma Overview
- Therapeutics Development
- An Overview of Pipeline Products for Kaposi's Sarcoma
- Kaposi's Sarcoma Therapeutics under Investigation by Universities/Institutes
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Kaposi's Sarcoma Therapeutics – Products under Investigation by Universities/Institutes
- Kaposi's Sarcoma – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Small Interference Ribonucleic Acids - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Liposomal Doxorubicin + Bevacizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Vincristine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- vif1 Peptide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Kaposi's Sarcoma Therapeutics – Discontinued Products
- Kaposi's Sarcoma Therapeutics - Dormant Products
- Appendix
Methodology - Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Kaposi's Sarcoma, H1 2012
- Products under Development for Kaposi's Sarcoma – Comparative Analysis, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
- Kaposi's Sarcoma Therapeutics – Discontinued Products
- Kaposi's Sarcoma Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Kaposi's Sarcoma, H1 2012
- Products under Development for Kaposi's Sarcoma – Comparative Analysis, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Mid Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
AbstractKaposi's Sarcoma – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Kaposi's Sarcoma - Pipeline Review, H1 2012', provides an overview of the Kaposi's Sarcoma therapeutic pipeline. This report provides information on the therapeutic development for Kaposi's Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kaposi's Sarcoma. 'Kaposi's Sarcoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Kaposi's Sarcoma.
- A review of the Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kaposi's Sarcoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Kaposi's Sarcoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Kaposi's Sarcoma pipeline depth and focus of Kaposi's Sarcoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
